Septin9 and BCAT1 methylation detection kit
Phase 1- Indications
- Colorectal cancer
Company intelligence / Profile preview
Xiamen Tengji Biotechnology
Xiamen, Fujian Sheng, Chinachictr.org.cn ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company has a small molecule drug NM6603 targeting RXRA (Retinoid X receptor alpha) in Phase 1 clinical trials that began on August 31, 2023.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Xiamen Tengji Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiamen Tengji Biotechnology.